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Objectives. This study sought to test the effect on thrombus
score of the “rescue” utilization of the glycoprotein IIb/IIIa
antagonist abciximab given to patients in whom intracoronary
thrombus has developed as a complication after percutaneous
transluminal coronary angioplasty (PTCA) and to determine its
clinical utility.
Background. Abciximab is effective in the prevention of acute
ischemic complications when given prophylactically to patients
during high risk PTCA. However, its ability to therapeutically
dissolve newly formed intracoronary thrombus occurring as a
complication after PTCA is not known.
Methods. We performed an observational study in 29 consecu-
tive patients who received abciximab (0.25 mg/kg body weight
intravenous bolus, followed by a 12-h infusion at 10 mg/min) after
attempted PTCA caused either the new development or further
progression of thrombus. Angiograms were analyzed to determine
thrombus score and Thrombolysis in Myocardial Infarction
(TIMI) flow grade before and after abciximab. Procedural and
clinical success and long-term outcome were also determined.
Results. Thrombus score decreased from 3.0 6 0.9 (mean 6
SD) to 0.86 6 0.92 (p < 0.001), and TIMI flow grade increased
from 2.5 6 0.7 to 2.9 6 0.3 (p 5 0.008). No instances of distal
embolization or no-reflow were noted. The procedural success
(<250% residual stenosis) rate was 97%. The clinical success
(procedural success with no in-hospital myocardial infarction,
bypass surgery or death) rate was 93%.
Conclusions. Dissolution of thrombus and restoration of TIMI
grade 3 flow were readily achieved after administration of abcix-
imab when delivered in a “rescue” manner after the development
of thrombosis after PTCA. This novel use of abciximab will need
to be validated in randomized trials.
(J Am Coll Cardiol 1997;30:1729–34)
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Percutaneous transluminal coronary angioplasty (PTCA) has
become a well accepted technique for revascularization in a
large variety of patients who present with symptomatic coro-
nary artery disease. However, this procedure continues to be
plagued by the complications of abrupt closure and restenosis
(1,2). Abciximab, the recently Food and Drug Administration
(FDA)-approved platelet glycoprotein IIb/IIIa receptor antag-
onist, through prevention of platelet aggregation and coronary
thrombosis, has shown promise in helping to decrease the
incidence of both of these complications when prophylactically
administered in patients presenting with unstable angina or
complex lesion morphology for PTCA (3–4) and in lower risk
patients as well (5). However, the cost of abciximab and its
associated increased risk of bleeding may limit its use as a
prophylactic treatment, leaving the opportunity open for new
thrombus to form during the angioplasty procedure. Whether
abciximab, when administered as a “rescue” procedure after
thrombus has developed, is beneficial and whether it has the
ability to therapeutically dissolve preexisting intracoronary
thrombus is not known.
Therefore, this study sought to evaluate the effect on
thrombus grade and Thrombolysis in Myocardial Infarction
(TIMI) flow grade of the “rescue” administration of abciximab
given therapeutically in patients after the development of
coronary thrombosis during angioplasty. The clinical outcome
of patients treated in this manner was also evaluated.
Methods
Procedure. A total of 53 of the 338 patients undergoing
coronary balloon angioplasty from April 1, 1995 to October 1,
1995 at our institution received abciximab and were evaluated
for the study. The investigations were performed in accordance
with the usual ethical guidelines of the hospital. Patients were
included in whom the abciximab was administered, after at
least one balloon inflation was performed, for the treatment of
the further progression or new development of coronary
thrombosis. This cohort included 29 patients. The other 24
patients received abciximab either prophylactically at the be-
ginning of the procedure or during angioplasty for reasons
other than thrombosis and were not included in this study.
Angioplasty was performed using standard techniques. All
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patients received premedication with aspirin (325 mg/day) and
intravenous heparin titrated to an activated clotting time
.300 s during the procedure. Balloon catheters were chosen
and used at the operator’s discretion. In general, a balloon/
artery ratio 1:1 was sought. After one or more balloon infla-
tions, repeat angiography was performed. After the develop-
ment of new coronary thrombus was evident, the patient was
given a bolus of intravenous abciximab (0.25 mg/kg body
weight), followed by a 12-h infusion at 10 mg/min. After the
administration of abciximab, further balloon inflations were
performed at the operator’s discretion. At the completion of
the procedure, final coronary angiograms were obtained to
determine procedural success. After angioplasty, heparin was
maintained or discontinued, and vascular sheaths were re-
moved at the discretion of the individual operator. Aspirin was
continued in all cases.
Data collection. For each patient, routine demographic
and clinical data, procedural results and in-hospital complica-
tions (defined later) were prospectively entered into a comput-
erized databank. All data were verified by retrospective review
of patient records.
Angiographic analysis. Lesions were assessed using an-
giography with multiple orthogonal views. Angiograms were
analyzed before the procedure, just before the administration
of abciximab and after the procedure. Cineangiograms were
interpreted by two experienced angiographers (J.B.M., L.A.K.)
for morphologic features similar to those used in the American
College of Cardiology/American Heart Association guidelines
(6). Visual determination of percent diameter stenosis (in the
most severe view) was performed using an ordinal scale (0,
,25%, 25%, 50%, 75%, 95% and 100%) that was previously
validated by comparison with pathologic measurements (7).
Visual determination of coronary thrombus score was per-
formed using the previously reported TIMI scale of 0 to 4 (0 5
no thrombus; 1 5 haziness; 2 5 definite thrombus ,1⁄2 vessel
diameter; 3 5 definite thrombus 1⁄2 to 2 vessel diameters; 4 5
definite thrombus .2 vessel diameters) (8,9). New development
of thrombus was defined as an increase in the coronary
thrombus grade by at least one level during the course of the
angioplasty procedure. Visual determination of coronary flow
was performed using the TIMI flow scale (0 5 no flow past the
lesion; 1 5 flow past the lesion but not filling the entire vessel;
2 5 flow past the lesion filling the entire vessel, but slower than
that of nonaffected vessels; 3 5 normal flow) (10).
Definitions. The following definitions were utilized: Proce-
dural success 5 procedure completed without death or bypass
surgery and a final residual stenosis #50%, as determined by
visual estimation; visual estimation was used instead of digital
quantitative measurements because this reflects clinical prac-
tice. Abrupt closure 5 total occlusion (TIMI grade 0 or 1 flow)
of the dilated segment occurring either in or out of the
laboratory before hospital discharge. Major in-hospital compli-
cations 5 death, myocardial infarction (MI) (creatine kinase,
MB fraction, more than twice the upper limit of normal) or
coronary artery bypass surgery (CABG) before hospital dis-
charge. Clinical success 5 procedural success without major
in-hospital complications. Major bleeding complications 5 in-
tracranial bleeding or overt bleeding associated with a de-
crease in hemoglobin .5 g/dl or a decrease in hematocrit $15
percentage points.
Long-term clinical follow-up. Patients discharged with a
clinically successful procedure were followed up for a mini-
mum of 6 months. Major clinical complications of death, MI or
need for repeat revascularization (repeat PTCA or CABG)
were documented.
Statistics. Categoric data are presented as proportions,
and continuous data are presented as mean value 6 SD.
Statistical comparisons were performed using chi-square anal-
ysis for categoric variables and the Student t test for continuous
variables. A p value #0.05 was considered significant.
Results
Patient demographics. Demographic data for the study
patients are shown in Table 1. A high proportion of patients
were men and had hypertension or hypercholesterolemia.
Most patients had been admitted with the acute ischemic
syndromes of unstable angina (52%) or acute MI (45%).
Abbreviations and Acronyms
CABG 5 coronary artery bypass grafting
EPIC 5 Evaluation of IIb/IIIa Platelet Receptor
Antagonist 7E3 in Preventing Ischemic
Complications (trial)
EPILOG 5 Evaluation of PTCA to Improve Long-Term
Outcome by C7E3 GPIIa/IIIa Receptor Blockade
FDA 5 Food and Drug Administration
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary angioplasty
TIMI 5 Thrombolysis in Myocardial Infarction
Table 1. Demographics of 29 Study Patients
Age (yr) 61 6 10
Male 86%
Past cardiovascular history
Previous PTCA 14%
Previous CABG 14%
Previous MI 7%
Atherosclerotic risk factors
Hypertension 76%
Diabetes mellitus 21%
Hypercholesterolemia 62%
Family history of CAD 48%
Cigarette smoking 31%
Indication for procedure
Stable angina 3%
Unstable angina 52%
Post MI (elective) 45%
Data presented are mean 6 SD or percent of patients. CABG 5 coronary
artery bypass graft surgery; CAD 5 coronary artery disease; MI 5 myocardial
infarction; PTCA 5 percutaneous transluminal coronary angioplasty.
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Lesion characteristics. Lesion characteristics are shown in
Table 2. Most procedures were performed in native coronary
vessels (94%), with more than half of these in the left anterior
descending coronary artery. The majority of target lesions were
judged to be of high clinical risk and were graded as type B or
C according to the American College of Cardiology/American
Heart Association classification (6). In 48% of instances, some
degree of intralesional thrombus was noted before the proce-
dure.
Procedural characteristics. Balloon angioplasty was uti-
lized as the treatment modality in all cases. In every instance,
at least two balloon inflations were performed before the
decision was made to begin abciximab treatment. In four cases,
abciximab was given after failed intracoronary urokinase ad-
ministration. In each case, at least one more balloon inflation
was performed after abciximab administration. Table 3 shows
the angiographic results of percent stenosis, thrombus score
and TIMI flow noted within the target vessel before the
procedure, immediately before delivery of abciximab and at
the end of the procedure. A significant improvement occurred
in all three values. Figure 1 shows a representative case study.
Acute results. The “rescue” use of abciximab during bal-
loon angioplasty resulted in procedural success in 28 (97%) of
29 cases. No instances of distal embolization or no-reflow were
noted. No patients required emergent surgery directly from the
catheterization laboratory; no patients experienced procedural
MI; and one patient had a partially successful (60% final
residual stenosis) but uncomplicated acute result. Four pa-
tients (14%) experienced transient abrupt occlusion during the
initial procedure. During the remaining hospital course, no
patient had abrupt reocclusion, repeat PTCA or acute MI;
however, one patient (3%) had CABG. Heparin was main-
tained for an average of 18 6 9 h after completion of the
procedure. Major bleeding complications occurred in two
(7%) patients: one in whom a major groin hematoma required
the use of blood transfusion and one in whom acute severe
posterior pharyngeal bleeding of unclear etiology developed,
resulting ultimately in death. Thus, overall clinical success was
achieved in 93%.
Long-term follow-up. All 27 patients with a clinically suc-
cessful procedure were discharged from the hospital and were
followed up for at least 6 months, with an average clinical
follow-up of 213 6 39 days. No deaths occurred. Two patients
experienced an MI, and six underwent repeat revascularization
(PTCA in four, CABG in two). At the end of the follow-up
period, 20 patients (74%) remained event free (Fig. 2).
Discussion
The new development of thrombus during an angioplasty
procedure can be very difficult to manage. In many instances,
thrombus forms despite high levels of preexisting anticoagula-
tion with heparin. Additional heparin or the use of intracoro-
nary administration of thrombolytic agents has been used with
at best marginally beneficial results (11), which leads to the
consideration of a platelet-mediated etiology for the progres-
sive thrombosis. The ability of abciximab to prevent the
development of thrombosis after high risk angioplasty is well
documented. The present study provides evidence of its ability
to also assist in the therapeutic dissolution of intracoronary
thrombus that has newly developed as a complication after
PTCA.
The ability of abciximab to dissolve a forming thrombus
may result from its ability to displace fibrinogen already bound
to the glycoprotein IIb/IIIa receptor because the affinity con-
stant for the binding of abciximab to the IIb/IIIa receptor is
significantly greater than that for fibrinogen binding. Addition-
ally, abciximab has been shown (12,13) to inhibit the action of
plasminogen activator inhibitor (PAI-1), which may disinhibit
Table 3. Effect of Abciximab Administration on Target Vessel
Stenosis, Thrombus Grade and TIMI Flow Grade
Pre-PTCA Pre-Abciximab Post-Abciximab p Value*
Percent stenosis 93 6 4% 57 6 22% 21 6 16% ,0.001
Thrombus grade 1.4 6 1.3 3.0 6 0.9 0.86 6 0.92 ,0.001
TIMI flow grade 2.5 6 1.0 2.5 6 0.7 2.9 6 0.3 0.008
*Pre-abciximab versus post-abciximab values. Data presented are mean
value 6 SD. Post-Abciximab 5 at last injection before leaving the catheterization
laboratory; Pre-Abciximab 5 at last injection before abciximab administration;
TIMI 5 Thrombolysis in Myocardial Infarction.
Table 2. Lesion Characteristics in 29 Study Patients
Location
Left anterior descending coronary artery 52%
Left circumflex coronary artery 14%
Right coronary artery 28%
Bypass graft 6%
Length
,5 mm 3%
5–20 mm 90%
.20 mm 7%
Angulation
Moderate 24%
Excessive 14%
Calcification 14%
Eccentric 62%
Thrombus 48%
Proximal vessel tortuosity 24%
ACC/AHA lesion type
A 2%
B 49%
C 49%
Data presented are percent of patients. ACC/AHA lesion type 5 American
College of Cardiology/American Heart Association classification of coronary
lesions based on risk of treatment; type A 5 absence of any type B or C
characteristics; type B 5 presence of one or more of the following moderate risk
lesion characteristics in the absence of any C characteristics: 10- to 20-mm
length, eccentric, moderate tortuosity of the proximal segment; 45° to 90°
angulation, irregular contour, calcification, ,3 month’s total occlusion, ostial
location, bifurcation lesion, thrombus; type C 5 presence of one or more of the
following high risk lesion characteristics: .20-mm length, excessive tortuosity of
the proximal segment, .90° angulation, .3 month’s total occlusion, inability to
protect major side branches, degenerated vein grafts with friable lesions.
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the natural thrombolytic pathway and result in further fibrino-
lysis.
Another possible mechanism of thrombus resolution, in the
present study, may relate to a combination of mechanical and
pharmacologic effects. After the development of new thrombus
after one or more balloon inflations, abciximab was adminis-
tered in a “rescue” manner that, in each case, was followed by
one or more repeat balloon inflations. The mechanical disrup-
tion of the platelet thrombus by balloon inflation in addition to
the prevention of the formation of new thrombus by abciximab
together may have played a role in the ultimate dissolution of
thrombus.
The present study demonstrates the beneficial effects on
thrombus burden of the “rescue” administration of abciximab
in cases of balloon angioplasty complicated by the new devel-
opment of thrombus. Although it is difficult to determine from
this small study whether an equivalent clinical benefit can be
obtained through the rescue use of abciximab in this manner
compared with its preprocedural administration, these results
do suggest a clinical benefit similar to that found in the
Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in
Preventing Ischemic Complications (EPIC) trial (3). In in-
stances in which, for whatever reason, abciximab was not
administered initially at the start of the procedure, later
administration does appear to be justified in the event of new
thrombus formation.
Figure 1. Coronary angiograms from a 65-year old man with a recent inferior MI
reperfused with thrombolysis. A, Subtotal irregular stenosis in the proximal right coronary
artery. B, Lesion after multiple balloon inflations, including a 15-min prolonged perfusion
balloon dilation. Multiple filling defects consistent with the new development of coronary
thrombus can be seen within the vessel lumen. C, Lesion 10 min after administration of
abciximab. A significant resolution of coronary thrombus can be seen.
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Despite the documented clinical efficacy of the prophylactic
use of abciximab during coronary angioplasty, concerns regard-
ing the cost of its use still exist (14). If all patients who met
criteria for enrollment in either the EPIC (3) or Evaluation of
PTCA to Improve Long-Term Outcome by C7E3 GPIIb/IIIa
Receptor Blockade (EPILOG) (15,16) trial were routinely
treated with abciximab before angioplasty, a majority of pa-
tients would be prophylactically treated. Although certain very
high risk categories of patients may still benefit from prophy-
lactic treatment, a possible strategy to be tested in lower risk
patients may include limiting abciximab administration to
those with intraprocedural thrombus development.
Two patients experienced major bleeding complications
after administration of abciximab in addition to aspirin and
heparin in the present study. This 7% incidence is similar to
that reported in the EPIC trial (17) and was not unexpected
because the postoperative management of heparin and femo-
ral sheaths was similar in both groups. Whether the use of
lower doses of heparin and earlier sheath withdrawal, as was
done in the EPILOG trial, will result in similar clinical
outcomes but with less bleeding complications in this group of
patients will require further study.
Limitations of the study. The two major limitations of this
study are its small numbers and its observational nature. Also,
by necessity, the angiographic interpretation was not per-
formed in blinded manner, which might introduce some bias.
Although a statistically significant difference in the thrombus
grade before and after abciximab was determined, the clinical
impact of this finding can only be determined through larger
randomized trials. Further randomized trials will also be
required to determine the safety and efficacy of a strategy of
routine administration of abciximab only in rescue circum-
stances.
Conclusions. Dissolution of thrombus and restoration of
TIMI grade 3 flow were readily achieved after administration
of abciximab when delivered in a rescue manner after the new
development of thrombosis after coronary angioplasty. Failure
to give preprocedural prophylactic abciximab did not appear to
exclude the possibility of a beneficial effect of abciximab, given
therapeutically during the early stages of thrombus formation,
in this subset of patients. By implication, platelets appear to
play a critical pathophysiologic role in this setting. This novel
use of abciximab will need to be validated in additional
prospective trials.
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